Lupin Announces Closure of Inspection by U.S. FDA at its Nagpur Unit-1 Facility with No Observations

Global pharma major Lupin Limited has announced the successful completion of a product specific Pre-Approval Inspection by the United States Food and Drug Administration (U.S. FDA) at its Unit-1 oral solid dosage manufacturing facility in Nagpur, India. The inspection, which took place from November 10 to November 14, 2025, concluded with zero 483 observations. This successful outcome exemplifies Lupin's commitment to upholding and maintaining the highest standards of quality, compliance, and safety across its facilities. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients, and has a strong presence in India and the U.S. across multiple therapy areas.